| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 06/30/2004 | EP1008341B1 Glucose-containing preparation |
| 06/30/2004 | EP0862628B1 Receptor and nucleic acid molecule encoding said receptor |
| 06/30/2004 | EP0690722B1 Composition and method for reducing toxicity of biologically-active factors |
| 06/30/2004 | CN1509462A Use of NF-kappa-B inhibitors in treatment of dry disorders |
| 06/30/2004 | CN1509292A Combination apparoach to treatment of cancer using C-MYC antisense oligomer |
| 06/30/2004 | CN1509283A Novel pyridyl cyanoguandine compounds |
| 06/30/2004 | CN1509184A Antipruritscs |
| 06/30/2004 | CN1509183A Use of proteasome inhibitors to treat dry eye disorders |
| 06/30/2004 | CN1509180A Method for treating syndrome X with aliphatic polyamines |
| 06/30/2004 | CN1509175A Novel Use |
| 06/30/2004 | CN1509168A Novel treatment for obsessive-compulsive disorder (OCD) and OCD-related disorders using GVG |
| 06/30/2004 | CN1509164A System for delivering consmetics and pharmaceuticals. |
| 06/30/2004 | CN1507917A Medicine containing nitric oxide synthase inhibitor for treating diabetes |
| 06/30/2004 | CN1507869A Combined preparation containing morpholine anthracyclines and anticancer agent |
| 06/30/2004 | CN1155602C Thineopyranecarboxyamide derivatives |
| 06/30/2004 | CN1155574C Ether muscarinic antagonists |
| 06/30/2004 | CN1155410C Composition for treatment of nicotine addiction containing a nicotine receptor antagonist and an anti-depressant or anti-anxiety drug |
| 06/30/2004 | CN1155409C Medical compsns. for preventing and treating arteriosclerotic desease |
| 06/30/2004 | CN1155402C Compounds that inhibit interaction between signal-transducing proteins and GLGF(PDZ/DHR) domain and uses thereof |
| 06/30/2004 | CN1155379C Use of Yiliqutan in preparing medicine for preventing recurrence of cephalagra |
| 06/30/2004 | CN1155378C Antitumour synergistic composition |
| 06/29/2004 | US6756491 Receptor polypeptide for use in the treatment of urogenital disorders and cushing's syndrome |
| 06/29/2004 | US6756481 IL-23 receptor binding compositions |
| 06/29/2004 | US6756480 Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein |
| 06/29/2004 | US6756401 Drug mixtures comprising estrogen agonists or antagonists and anticholesterol statins, administered to promote bone formation, prevent bone disorders and/or as anticholesterol agents |
| 06/29/2004 | US6756399 Use of lipoxygenase inhibitors and PPAR ligands as anti-cancer therapeutic and intervention agents |
| 06/29/2004 | US6756398 Positive modulators of nicotinic receptor agonists |
| 06/29/2004 | US6756392 Carbocyclic secondary amides such as 2-(4-fluoro-phenoxy) -n-(4-((2-hydroxy-3-methyl-benzoyl amino)-methyl)-benzyl)-nicotinamide, administered for prophylaxis of respiratory system disorders |
| 06/29/2004 | US6756369 Administering to the patient at least two agents, each of which is effective against a different phase of chlamydial life cycle, until the biological material is negative for chlamydia |
| 06/29/2004 | US6756364 Method of reducing gastrointestinal side effects associated with orlistat treatment |
| 06/29/2004 | US6756360 Combination of FBPase inhibitors and insulin sensitizers for the treatment of diabetes |
| 06/29/2004 | US6756213 Nucleic acid encoding retinoic acid receptor |
| 06/29/2004 | US6756060 Anti-inflammatory and antimicrobial uses for bioactive glass compositions |
| 06/29/2004 | US6756055 Administering to a mammal formulation of cationic lipids and a substance that affects angiogenesis; allowing formulation to associate with angiogenic endothelial cells of an angiogenic blood vesselsuch that it enters cells |
| 06/29/2004 | US6756053 Establishing a drug depot in tissues under the user's skin surface by applying a transdermal drug delivery system on a user's skin; allowing transdermal drug delivery system to be applied on skin area without heating; placing heating source |
| 06/29/2004 | US6756052 Effects localized increase in temperature and/or blood flow using rubefacient agent |
| 06/29/2004 | US6756047 Method and compositions for treating persistent pulmonary hypertension using aralkyl ester soft drugs |
| 06/29/2004 | US6755856 Methods and apparatus for stenting comprising enhanced embolic protection, coupled with improved protection against restenosis and thrombus formation |
| 06/29/2004 | CA2296726C Combination therapy |
| 06/29/2004 | CA2293815C Film-coated tablet for improved upper gastrointestinal tract safety |
| 06/29/2004 | CA2280685C A medicament against infertility and for increasing fertility |
| 06/29/2004 | CA2275392C New aqueous medicament preparations for the production of propellent gas-free aerosols |
| 06/29/2004 | CA2031518C Endothelial cell-leukocyte adhesion molecules (elams) and molecules involved in leukocyte adhesion (milas) |
| 06/24/2004 | WO2004052461A1 Combination for the treatment of adhd |
| 06/24/2004 | WO2004052399A1 Composition for topical anesthesia |
| 06/24/2004 | WO2004052390A1 Methods and compositions for treating polycystic ovary syndrome |
| 06/24/2004 | WO2004052376A1 Method of reducing toxicity of anticancer agents |
| 06/24/2004 | WO2004052369A1 Pharmaceutical combinations and methods for the treatment of leukemia |
| 06/24/2004 | WO2004052349A2 Compositions comprising a combination of diphenyl ura impdh inhibitors and apoptosis-inducing anti-cancer agents |
| 06/24/2004 | WO2004052346A1 Pharmaceutical compositions containing indistinguishable drug components |
| 06/24/2004 | WO2004052315A2 Tyrosine kinase inhibitors |
| 06/24/2004 | WO2004052308A2 Topical anti-infective formulations |
| 06/24/2004 | WO2004052296A2 Dioxolane thymine and combinations for use against 3tc/ azt resistant strains of hiv |
| 06/24/2004 | WO2004052295A2 Compositions and methods for nutrition supplementation |
| 06/24/2004 | WO2004052292A2 Histone deacetylase inhibitor enhancement of trail-induced apoptosis |
| 06/24/2004 | WO2004052286A2 Tyrosine kinase inhibitors |
| 06/24/2004 | WO2004052285A2 Fat regulation |
| 06/24/2004 | WO2004052177A2 Cell-based therapies for ischemia |
| 06/24/2004 | WO2004052123A1 Zinc-rich foods having effect of preventing diabetes |
| 06/24/2004 | WO2004030625A3 Synergistic methods and compositions for treating cancer |
| 06/24/2004 | WO2004024896A3 Phenyl-indole compounds |
| 06/24/2004 | WO2004024883A3 PAKs AS MODIFIERS OF THE CHK PATHWAY AND METHODS OF USE |
| 06/24/2004 | WO2004022002A3 Combined immediate release and extended release analgesic composition |
| 06/24/2004 | WO2004020403A3 A composition and method to augment and sustain neurotransmitter production |
| 06/24/2004 | WO2004014304A3 Electrospun amorphous pharmaceutical compositions |
| 06/24/2004 | WO2004011650A3 Antigens encoded by alternative reading frame from pathogenic viruses |
| 06/24/2004 | WO2004010953A3 Implantable artificial organ devices |
| 06/24/2004 | WO2004005474A3 A robust, inducible cardiac preferred expression system for transgenesis |
| 06/24/2004 | WO2003105724A3 Novel maxi-k channel blockers, methods of use and process for making the same |
| 06/24/2004 | WO2003103699A8 Use of ramoplanin to treat diseases associated with the use of antibiotics |
| 06/24/2004 | WO2003101389B1 Relief of aids symptoms |
| 06/24/2004 | WO2003099221A3 Methods for using jnk inhibitors for treating or preventing disease-related wasting |
| 06/24/2004 | WO2003092580B1 Methods and compositions for treatment of central and peripheral nervous system disorders and novel compounds useful therefor |
| 06/24/2004 | WO2003086311A3 Methods for treating tweak-related conditions |
| 06/24/2004 | WO2003076631A3 Genetic products differentially expressed in tumors and use thereof |
| 06/24/2004 | WO2003072056A3 Intranasal administration of mc4-r agonists |
| 06/24/2004 | WO2003057200A3 Compositions comprising inhibitors of dpp-iv and nep enzymes for the treatment of diabetes |
| 06/24/2004 | WO2003053966A8 1-alkyl-1-azoniabicyclo [2.2.2] octane carbamate derivatives and their use as muscarinic receptor antagonists |
| 06/24/2004 | WO2003051841A3 Compounds and uses thereof for decreasing activity of hormone-sensitive lipase |
| 06/24/2004 | WO2003049686A3 Stabilization of hypoxia inducible factor (hif) alpha |
| 06/24/2004 | WO2003024386A8 Use of potent, selective and non toxic c-kit inhibitors for treating interstitial cystitis |
| 06/24/2004 | WO2003014309A3 Interleukin-1 receptors in the treatment of diseases |
| 06/24/2004 | WO2003008560A8 A novel g protein-coupled receptor, gave8 |
| 06/24/2004 | WO2002092594A8 Substituted 4h-chromenes and analogs as activators of caspases and inducers of apoptosis and the use thereof |
| 06/24/2004 | WO2002038141A3 Compositions and methods for treatment of mild cognitive impairment |
| 06/24/2004 | WO2002036072A3 Method for short-term and long-term drug dosimetry |
| 06/24/2004 | US20040122235 such as N-(2-Phenoxyphenyl)-N'-(thiazol-2-yl)urea; for treating diseases in which increasing glucokinase activity is beneficial (diabetes) |
| 06/24/2004 | US20040122234 Growth Hormone secretagogues |
| 06/24/2004 | US20040122109 Preparation for hair and/or scalp |
| 06/24/2004 | US20040122108 Betamimetics with a prolonged duration of activity, processes for preparing them, and their use as pharmaceutical compositions |
| 06/24/2004 | US20040122105 Transdermal compositions |
| 06/24/2004 | US20040122097 Stimulation of in vivo production of proteins |
| 06/24/2004 | US20040122080 Synergist combinations of retinoid receptor ligands and selected cytotoxic agents for treatment of cancer |
| 06/24/2004 | US20040122078 A compound having slowly-deactivating A-type K+ channel opening activity such as N-(5,5-dioxido-10-oxo-4,10-dihydrothieno[3,2-c][1]benzothiepin-9-yl)-3,3,3-trifluoro-2-hydroxy-2-methylpropanamide |
| 06/24/2004 | US20040122077 Administering a statin drug in an amount to promote angiogenesis in the tissue, preferably in situations where the subject is not otherwise in need of the drug ; activating Akt (protein kinase B) in vascular endothelial cells in vitro and in vivo |
| 06/24/2004 | US20040122068 Pramipexole and salts, e.g. dichloride, for use in the prevention and/or treatment of HIV-associated encephalopathy; motor disorders, cognitive impairment and behavioural disorders;.brain disorders; cognition activators |
| 06/24/2004 | US20040122062 such as 2-amino-N-(2-(3a-(R)-benzyl-2-methyl-3-oxo-2,3,3a,4,6,7-hexahydro-pyrazolo-[4,3-c]pyridin-5-yl)-1-(R)-benzyloxymethyl-2-oxo-ethyl)-isobutyramide |
| 06/24/2004 | US20040122052 Isoindolin-1-one and Isoindoline-1,3-dione substituted in the 2-position with a 2,6-dioxo-3-hydroxypiperidin-5-yl group or derivative; selectively inhibit TNF alpha, useful in treating inflammation and effecting relaxation of airway smooth muscle |
| 06/24/2004 | US20040122042 nitrogen containing heterocyclic compounds as chymase inhibitor together with ace enzyme inhibitor are effective for the treatment of hypertension and cardiac disease |
| 06/24/2004 | US20040122036 Pharmaceutical combinations based on pyridoindolone derivatives and anticancer agents |